Gliclazide
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
| |
| Gliclazide
| |
| Systematic (IUPAC) name | |
| 3-(7-azabicyclo[3.3.0]oct-7-yl)- 1-(4-methylphenyl)sulfonyl-urea | |
| Identifiers | |
| CAS number | |
| ATC code | A10 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C15H21N3O3S |
| Mol. mass | 323.412 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
|
WikiDoc Resources for Gliclazide | |
|
Articles | |
|---|---|
|
Most recent articles on Gliclazide | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Gliclazide at Clinical Trials.gov Clinical Trials on Gliclazide at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Gliclazide
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Gliclazide Discussion groups on Gliclazide Patient Handouts on Gliclazide Directions to Hospitals Treating Gliclazide Risk calculators and risk factors for Gliclazide
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Gliclazide | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Gliclazide is an oral hypoglycemic (anti-diabetic drug) and is classified as a sulfonylurea. It is marketed as Diamicron MR®. DIAMICRON MR is also distributed as: Diabeton MR, Diamicron 30mg, Diamicron LM 30mg, Diamicron MR 30 mg, Diamicron Uno 30mg, Dianormax MR, Diaprel MR and Uni Diamicron.
Form and Composition:
Each tablet contains 80 mg of gliclazide.
Not marketed in the United States.
Indication:
Control of hyperglycemia in gliclazide responsive diabetes mellitus of stable, mild, non-ketosis prone, maturity onset or adult type which cannot be controlled by proper dietary management and exercise, or when insulin therapy is not appropriate.
Dosage:
40 to 240 mg depending on response, once or twice daily before food, no more that 160 mg at a time.
Properties:
Hypoglycemic sulfonylurea, restoring first peak of insulin secretion, increasing insulin sensitivity. Glycemia-independent hemovascular effects, antioxidant effect. No active circulating metabolites.
Contraindications:
type 1 diabetes, hypersensitivity to sulfonylureas, severe renal or hepatic failure, pregnancy and lactation, miconazole coprescription.
Interactions:
Hyperglycemic action may be caused by danazol, chlorpromazine, glucocorticoids, progestogens, β-2 agonists. Its hypoglycemic action may be potentiated by phenylbutazone, alcohol, fluconazole, β-blockers, possibly ACE inhibitors.
Adverse effects:
Hypoglycemia, gastrointestinal disturbance (reported), skin reactions (rare), hematological disorders (rare), hepatic enzyme rises (exceptional).
Overdosage:
Possible severe hypoglycemia requiring urgent IV glucose and monitoring.
External links
Oral antidiabetic drugs and Insulin analogs (A10) | |
|---|---|
| Biguanides | Metformin |
| Sulfonylureas | Chlorpropamide, Glibenclamide (Glyburide), Gliclazide, Glimepiride, Glipizide, Gliquidone, Tolazamide, Tolbutamide |
| Alpha-glucosidase inhibitors | Acarbose, Miglitol, Voglibose |
| Thiazolidinediones (TZD) | Pioglitazone, Rivoglitazone†, Rosiglitazone, Troglitazone‡ |
| Meglitinides | Nateglinide, Repaglinide, Mitiglinide |
| Dipeptidyl peptidase-4 (DPP-4) inhibitors | Alogliptin†, Saxagliptin†, Sitagliptin, Vildagliptin, Linagliptin† |
| Glucagon-like peptide-1 analog | Exenatide, Liraglutide†, Albiglutide† |
| Amylin analog | Pramlintide |
| Insulin analogs | fast acting (Insulin lispro, Insulin aspart, Insulin glulisine), long acting (Insulin glargine, Insulin detemir) |
| Dual PPAR agonists | Aleglitazar†, Muraglitazar§, Tesaglitazar§ |
| SGLT2 inhibitor | Dapagliflozin†, Remogliflozin† |
| †Undergoing clinical trials. ‡ Withdrawn from market. §Development halted. | |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
